Solius Labs Launches Solius Pro with 99% Less UV Risk, Targets Home Market

Solius Labs' entry into the OTC light therapy space comes at a time when wellness tech startups are attracting significant venture interest. With a patent-pending skin analysis system and a unique FDA classification, the company could disrupt the home phototherapy market—if it can convince consumers and insurers of its value proposition.

Solius Labs announced the launch of Solius Pro, claiming it as the world's first FDA-cleared over-the-counter personalized UVB light therapy device. The device, revealed on June 17, 2026, uses a patent-pending skin analysis system to measure each user's unique skin tone and deliver a precise dose of UVB radiation. According to the company, this approach stimulates the natural health benefits of sunlight in approximately five minutes per week, with 99% less UV risk than the sun. The U.S. Food and Drug Administration established a new product code for the device, recognizing it as a novel health technology category and placing it in a distinct regulatory bracket.

“

Solius Labs announced the launch of Solius Pro, claiming it as the world's first FDA-cleared over-the-counter personalized UVB light therapy device.

The launch addresses a growing public health concern: insufficient sunlight exposure due to modern indoor lifestyles, geographic location, and seasonal variation. UVB wavelengths are critical for vitamin D synthesis, immune function, and mood regulation, yet safe dosing has historically required physician supervision. Solius Labs’ device aims to shift this paradigm by making personalized UVB therapy accessible at home without a prescription. The company asserts that a full year of weekly sessions delivers less UV exposure risk than five minutes of afternoon sun, and that Solius Pro emits 50% less total UV radiation than existing prescription narrowband UVB devices—though this claim was partially truncated in the release.

From a regulatory perspective, the FDA’s creation of a new product code signals acknowledgment of personalized phototherapy as a distinct medical device category. This could streamline future clearances for similar products and validates the underlying technology’s novelty. However, the announcement is entirely based on a company press release, and no independent clinical data, peer-reviewed studies, or third-party endorsements were provided. The claims of “12x more UVB biological benefit” and risk comparisons rely solely on Solius Labs’ internal testing and simulations; the precise metrics, endpoints, and validation methods remain undisclosed.

The market implications are significant. The global light therapy market, valued at over $1 billion, is expanding as consumers seek non-pharmacological wellness solutions. Solius Pro enters a niche that bridges the gap between therapeutic prescription devices (often reimbursed but inconvenient) and unregulated wellness gadgets. The OTC positioning could attract consumers wary of doctor visits or seeking preventative health tools. Yet, the device’s commercial success hinges on convincing a skeptical public and clinicians that the benefits outweigh the risks of repeated UVB exposure, even at low doses. Long-term safety data and real-world effectiveness for endpoints like vitamin D status or seasonal affective disorder are absent from the launch materials.